Norethisterone

Molina Healthcare of Ohio and Pacify Award Inaugural Diversity in Lactation Consulting Scholarship

Retrieved on: 
Monday, March 6, 2023
Consultant, Mortality, International Board, Diversity, Infant, Nabila, Education, Woman, Lactation, Mother, Mentorship, Lactation consultant, Health, Patient, Black, Human, Molina Healthcare, IBCLC, Knowledge, Norethisterone, Parent, Birth control, Nursing, Pharmaceutical industry, RD, COLUMBUS, Pacification

COLUMBUS, Ohio, March 6, 2023 /PRNewswire/ -- Molina Healthcare of Ohio and Pacify, a health technology company that provides 24/7 infant feeding support to new and expecting parents, have awarded four recipients the Diversity in Lactation Consulting Scholarship, the first of its kind in Ohio.

Key Points: 
  • COLUMBUS, Ohio, March 6, 2023 /PRNewswire/ -- Molina Healthcare of Ohio and Pacify , a health technology company that provides 24/7 infant feeding support to new and expecting parents, have awarded four recipients the Diversity in Lactation Consulting Scholarship, the first of its kind in Ohio.
  • Why is winning Pacify's Diversity in Lactation Consulting Scholarship so meaningful to you?
  • With Pacify's Diversity in Lactation Consulting Scholarship, this is what I hope to achieve.
  • "We are excited to offer the scholarship to four excellent recipients," said Ami Cole, plan president for Molina Healthcare of Ohio.

Bolt Biotherapeutics Appoints Laura Berner to Board of Directors

Retrieved on: 
Wednesday, December 14, 2022
Ropes & Gray, Estradiol, Office of the General Counsel for the Department of the Treasury, Roivant Sciences, Annual report, Stanford Law School, Harvard University, Security (finance), Business, Research Park at the University of Illinois Urbana-Champaign, Macrophage, Safety, Cancer, Rope, Doctor of Philosophy, Norethisterone, Bolt, Genentech, Immune stimulating antibody conjugate, ISAC, Bryn Mawr College, MBA, Research, Nivolumab, IND, General counsel, Biology, University, Patient, Business development, Management, Pharmaceutical industry

REDWOOD CITY, Calif., Dec. 14, 2022 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced the appointment of Laura Berner to its Board of Directors effective Dec. 14, 2022.

Key Points: 
  • REDWOOD CITY, Calif., Dec. 14, 2022 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced the appointment of Laura Berner to its Board of Directors effective Dec. 14, 2022.
  • “Laura is an accomplished biopharmaceutical executive with impressive corporate leadership, operations, and business development experience,” said Randall Schatzman, Ph.D., Chief Executive Officer of Bolt Biotherapeutics.
  • Bolt Biotherapeutics’ pipeline candidates are built on the Company’s deep expertise in myeloid biology and cancer drug development.
  • Bolt Biotherapeutics’ pipeline includes BDC-1001, a HER2-targeting Boltbody Immune-stimulating Antibody Conjugate (ISAC), BDC-3042, a myeloid-modulating antibody, and multiple Boltbody ISAC collaboration programs.

Myovant Sciences and Pfizer Receive U.S. FDA Approval of MYFEMBREE®, a Once-Daily Treatment for the Management of Moderate to Severe Pain Associated With Endometriosis

Retrieved on: 
Saturday, August 6, 2022
Linda, FDA, Woman, Hospital, Dysmenorrhea, UCSF, Endometriosis, NYSE, Internal medicine, GLOBE, University of California, San Francisco, NEW, Senior, Norethisterone, Roivant Sciences, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Pfizer, PFE, Pain, Patient, SPIRIT, Uterine fibroid, Safety, Rusyns, Webcast, Physician, University, Conditional sentence, Chair, Food, Health, Disease, Pharmaceutical industry, Dentistry, Lancet

MYFEMBREE offers an effective, once-daily treatment option for the management of moderate to severe pain associated with endometriosis, with a treatment duration of up to 24 months.

Key Points: 
  • MYFEMBREE offers an effective, once-daily treatment option for the management of moderate to severe pain associated with endometriosis, with a treatment duration of up to 24 months.
  • MYFEMBREE is available immediately to patients with moderate to severe pain associated with endometriosis with a prescription from their healthcare provider.
  • Myovant and Pfizer also are committed to supporting women in the U.S. who are prescribed MYFEMBREE throughout their treatment journeys.
  • Food and Drug Administration for the management of moderate to severe pain associated with endometriosis, with a treatment duration of up to 24 months.

Myovant Sciences and Pfizer Announce Publication in The Lancet of Phase 3 SPIRIT 1 and SPIRIT 2 Studies of Once-Daily Relugolix Combination Therapy in Women With Endometriosis-Associated Pain

Retrieved on: 
Friday, June 17, 2022
Pfizer, Roivant Sciences, Endometriosis, Dysmenorrhea, Week, GLOBE, Pain, NEW, SPIRIT, Dyspareunia, NYSE, Norethisterone, Woman, PFE, Pharmaceutical industry, Birth control, Medical imaging, Lancet

In both studies, relugolix combination therapy was associated with a generally well-tolerated safety profile, including bone mineral density loss of

Key Points: 
  • In both studies, relugolix combination therapy was associated with a generally well-tolerated safety profile, including bone mineral density loss of
  • Seven key secondary endpoints in SPIRIT 1 and six key secondary endpoints in SPIRIT 2 comparing relugolix combination therapy with placebo at Week 24 also achieved statistical significance.
  • The most frequently reported adverse events in both relugolix combination treatment and placebo groups were headache, nasopharyngitis, and hot flushes.
  • For endometriosis-associated pain, current treatment options include prescription and over-the-counter pain medications, oral contraceptives, GnRH agonists, and antagonists.

Tequity Advised Managed Services Firm Triella on their Acquisition by Miii MSP

Retrieved on: 
Tuesday, April 5, 2022
Cloud, 1003, MSP, Software as a service, SME, Norethisterone, Entrepreneurship, School, Software, Technology, Knowledge, Solution, Consultant, Member of the Scottish Parliament, Acquisition, Sales

Triella is a leading managed services provider in Toronto with in-depth knowledge in the legal sector.

Key Points: 
  • Triella is a leading managed services provider in Toronto with in-depth knowledge in the legal sector.
  • Triella helps its clients to maintain and enhance their underlying technology through consulting, assessments, and managed services and solutions.
  • Miii MSP are long-term growth investors in the MSP market with a mission to become North America's leading network of innovative, interactive, and integrated managed service providers.
  • Pamela Miranda, Co-Founder and Partner at Miii MSP said, "Working with Wilf Rapp and Tequity was an absolute pleasure.

ObsEva Announces Additional Efficacy Results for Linzagolix 200 mg with Add-Back Therapy (ABT) and Linzagolix 75 mg without ABT in the Phase 3 EDELWEISS 3 Trial in Patients with Moderate-to-Severe Endometriosis-Associated Pain

Retrieved on: 
Tuesday, March 22, 2022
EAP, Private Securities Litigation Reform Act, Menstrual cycle, Drug development, Nephrology Dialysis Transplantation, Risk, Norethisterone, Dyspareunia, Investor, Analgesic, SIX Swiss Exchange, Ovulation, EDELWEISS, Fertility, Clinical trial, Infertility, Birth certificate, Coronavirus, Uterine fibroid, Constipation, Urology, Pelvic pain, SEC, Pregnancy, Uterus, Research, Woman, Endometrium, Patient, CEO, Gonadotropin-releasing hormone, Pain, Gynaecology, Security (finance), Sexual intercourse, Safety, Defecation, ABT, Estradiol, U.S. Securities and Exchange Commission, Dysmenorrhea, Endometriosis, Nasdaq, Linzagolix, Fatigue, Disease, Pharmaceutical industry, Birth control, Kissei

EDELWEISS 3 (Europe and the U.S.) was a randomized, double-blind, placebo-controlled, Phase 3 trial that analyzed 484 women with moderate-to-severe EAP.

Key Points: 
  • EDELWEISS 3 (Europe and the U.S.) was a randomized, double-blind, placebo-controlled, Phase 3 trial that analyzed 484 women with moderate-to-severe EAP.
  • The study included a 200 mg once-daily dose in combination with ABT (1 mg estradiol / 0.5 mg norethindrone acetate), and a 75 mg once-daily dose without ABT.
  • Results from the post-treatment follow-up of EDELWEISS 3 are expected in early 3Q2022.
  • Results from the treatment phase of the extension study (EDELWEISS 6) and its post-treatment follow-up phase are expected in early 3Q2022 and 4Q2022, respectively.

ObsEva Announces Additional Efficacy Results for Linzagolix 200 mg with Add-Back Therapy (ABT) and Linzagolix 75 mg without ABT in the Phase 3 EDELWEISS 3 Trial in Patients with Moderate-to-Severe Endometriosis-Associated Pain

Retrieved on: 
Tuesday, March 22, 2022
EAP, Private Securities Litigation Reform Act, Menstrual cycle, Drug development, Nephrology Dialysis Transplantation, Risk, Norethisterone, Dyspareunia, Investor, Analgesic, SIX Swiss Exchange, Ovulation, EDELWEISS, Fertility, Clinical trial, Infertility, Birth certificate, Coronavirus, Uterine fibroid, Constipation, Urology, Pelvic pain, SEC, Pregnancy, Uterus, Research, Woman, Endometrium, Patient, CEO, Gonadotropin-releasing hormone, Pain, Gynaecology, Security (finance), Sexual intercourse, Safety, Defecation, ABT, Estradiol, U.S. Securities and Exchange Commission, Dysmenorrhea, Endometriosis, Nasdaq, Linzagolix, Fatigue, Disease, Pharmaceutical industry, Birth control, Kissei

EDELWEISS 3 (Europe and the U.S.) was a randomized, double-blind, placebo-controlled, Phase 3 trial that analyzed 484 women with moderate-to-severe EAP.

Key Points: 
  • EDELWEISS 3 (Europe and the U.S.) was a randomized, double-blind, placebo-controlled, Phase 3 trial that analyzed 484 women with moderate-to-severe EAP.
  • The study included a 200 mg once-daily dose in combination with ABT (1 mg estradiol / 0.5 mg norethindrone acetate), and a 75 mg once-daily dose without ABT.
  • Results from the post-treatment follow-up of EDELWEISS 3 are expected in early 3Q2022.
  • Results from the treatment phase of the extension study (EDELWEISS 6) and its post-treatment follow-up phase are expected in early 3Q2022 and 4Q2022, respectively.

Myovant Sciences Announces Preliminary Financial Results for Third Quarter of Fiscal Year 2021

Retrieved on: 
Monday, January 10, 2022
Infertility, Pain, Man, LinkedIn, Gonadotropin-releasing hormone, FDA, Health care, Webcast, Roivant Sciences, Total, New Drug Application, European Commission, Female, Pregnancy, Union, Private Securities Litigation Reform Act, Medication, Woman, Norethisterone, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Adoption, SEC, Gedeon Richter, Endometriosis, Patient, Uterine fibroid, Food, Therapy, NYSE, Risk, Twitter, GLOBE, Royal commission, ORGOVYX, Sumitomo Dainippon Pharma, Growth, Testosterone, Marketing, Conference, Adult, Relugolix, Review, Prostate cancer, U.S. Securities and Exchange Commission, Fossil fuel, Pharmaceutical industry, Fine chemical, Audit, Pfizer

Furthermore, this press release includes information regarding Myovant Sciences preliminary financial results for the third fiscal quarter ended December 31, 2021.

Key Points: 
  • Furthermore, this press release includes information regarding Myovant Sciences preliminary financial results for the third fiscal quarter ended December 31, 2021.
  • Myovant Sciences is currently in the process of finalizing its financial results for the third fiscal quarter ended December 31, 2021, and the preliminary financial results presented in this press release are based only on preliminary information available to Myovant Sciences as of January 10, 2022.
  • These preliminary financial results should not be viewed as a substitute for audited consolidated financial statements prepared in accordance with U.S. GAAP, and undue reliance should not be placed on Myovant Sciences preliminary financial results.
  • Myovant Sciences independent registered public accounting firm has not audited or reviewed the preliminary financial results included in this press release or expressed any opinion or other form of assurance on such preliminary financial results.

ObsEva Announces Positive Topline Results for Linzagolix 200 mg with Add-Back Therapy in the Phase 3 EDELWEISS 3 Trial in Patients with Moderate-to-Severe Endometriosis-Associated Pain

Retrieved on: 
Thursday, January 6, 2022
ID, EMA, Clinical trial, Endometriosis, Safety, Pelvic pain, Pregnancy, Urology, Uterine fibroid, Estradiol, Endometrium, Menstrual cycle, Sexual intercourse, Birth certificate, Investor, SIX Swiss Exchange, Patient, Uterus, Fertility, Dysmenorrhea, Nephrology Dialysis Transplantation, Gonadotropin-releasing hormone, Analgesic, BMD, Security (finance), Report, Risk, Private Securities Litigation Reform Act, Gynaecology, Central European Time, Disease, CEO, EAP, SEC, Norethisterone, Research, FDA, EDELWEISS, Woman, Infertility, Pain, Defecation, ABT, Dyspareunia, U.S. Securities and Exchange Commission, Drug development, Constipation, Headache, Linzagolix, Fatigue, Nasdaq, Coronavirus, Ovulation, Pharmaceutical industry, Birth control, Kissei

ObsEva will host a conference call and audio webcast with Dr. Hugh Taylor today, January 6 at 8:00 a.m. Eastern Time/2:00 p.m. Central European Time to discuss Phase 3 EDELWEISS 3 trial results of linzagolix.

Key Points: 
  • ObsEva will host a conference call and audio webcast with Dr. Hugh Taylor today, January 6 at 8:00 a.m. Eastern Time/2:00 p.m. Central European Time to discuss Phase 3 EDELWEISS 3 trial results of linzagolix.
  • Investors may participate by dialing 1-877-407-9208 for U.S. callers or +1-201-493-6784 for international callers and refer to conference ID 13725902.
  • EDELWEISS 3 (Europe and the U.S.) was a randomized, double-blind, placebo-controlled, Phase 3 trial that analyzed 484 women with moderate-to-severe EAP.
  • The study included a 200 mg once-daily dose in combination with ABT (1 mg estradiol / 0.5 mg norethindrone acetate), and a 75 mg once-daily dose without ABT.

ObsEva Announces Positive Topline Results for Linzagolix 200 mg with Add-Back Therapy in the Phase 3 EDELWEISS 3 Trial in Patients with Moderate-to-Severe Endometriosis-Associated Pain

Retrieved on: 
Thursday, January 6, 2022
ID, EMA, Clinical trial, Endometriosis, Safety, Pelvic pain, Pregnancy, Urology, Uterine fibroid, Estradiol, Endometrium, Menstrual cycle, Sexual intercourse, Birth certificate, Investor, SIX Swiss Exchange, Patient, Uterus, Fertility, Dysmenorrhea, Nephrology Dialysis Transplantation, Gonadotropin-releasing hormone, Analgesic, BMD, Security (finance), Report, Risk, Private Securities Litigation Reform Act, Gynaecology, Central European Time, Disease, CEO, EAP, SEC, Norethisterone, Research, FDA, EDELWEISS, Woman, Infertility, Pain, Defecation, ABT, Dyspareunia, U.S. Securities and Exchange Commission, Drug development, Constipation, Headache, Linzagolix, Fatigue, Nasdaq, Coronavirus, Ovulation, Pharmaceutical industry, Birth control, Kissei

We remain dedicated to providing flexible treatment options for women and look forward to further development of linzagolix in the endometriosis indication.

Key Points: 
  • We remain dedicated to providing flexible treatment options for women and look forward to further development of linzagolix in the endometriosis indication.
  • Investors may participate by dialing 1-877-407-9208 for U.S. callers or +1-201-493-6784 for international callers and refer to conference ID 13725902.
  • EDELWEISS 3 (Europe and the U.S.) was a randomized, double-blind, placebo-controlled, Phase 3 trial that analyzed 484 women with moderate-to-severe EAP.
  • The study included a 200 mg once-daily dose in combination with ABT (1 mg estradiol / 0.5 mg norethindrone acetate), and a 75 mg once-daily dose without ABT.